Business Description
Kancera AB
NAICS : 325412
SIC : 2834
ISIN : SE0015658570
Compare
Compare
Traded in other countries / regions
KAN.Sweden3EE0.Germany IPO Date
2011-03-10Description
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.93 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 13 | |||||
| Beneish M-Score | -2.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -52.8 | |||||
| 3-Year EBITDA Growth Rate | 4.4 | |||||
| 3-Year EPS without NRI Growth Rate | 56.1 | |||||
| 3-Year FCF Growth Rate | 8.7 | |||||
| 3-Year Book Growth Rate | -23.2 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.42 | |||||
| 9-Day RSI | 47.03 | |||||
| 14-Day RSI | 46.27 | |||||
| 6-1 Month Momentum % | -43.73 | |||||
| 12-1 Month Momentum % | -81.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.66 | |||||
| Quick Ratio | 10.66 | |||||
| Cash Ratio | 10.37 | |||||
| Days Sales Outstanding | 16468.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.3 | |||||
| Shareholder Yield % | -42.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -12468.62 | |||||
| Net Margin % | -12053.05 | |||||
| FCF Margin % | -13280 | |||||
| ROE % | -73.62 | |||||
| ROA % | -60.61 | |||||
| ROIC % | -131.53 | |||||
| ROC (Joel Greenblatt) % | -245.04 | |||||
| ROCE % | -75.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 0.42 | |||||
| PS Ratio | 232 | |||||
| PB Ratio | 1.95 | |||||
| Price-to-Tangible-Book | 2.99 | |||||
| EV-to-EBIT | -1.72 | |||||
| EV-to-EBITDA | -1.81 | |||||
| EV-to-Revenue | 214.19 | |||||
| EV-to-FCF | -1.58 | |||||
| Price-to-Median-PS-Value | 0.56 | |||||
| Price-to-Net-Current-Asset-Value | 2.99 | |||||
| Price-to-Net-Cash | 2.99 | |||||
| Earnings Yield (Greenblatt) % | -58.14 | |||||
| FCF Yield % | -42.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kancera AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.04 | ||
| EPS (TTM) (€) | -0.047 | ||
| Beta | 2.76 | ||
| Volatility % | 89.72 | ||
| 14-Day RSI | 46.27 | ||
| 14-Day ATR (€) | 0.006871 | ||
| 20-Day SMA (€) | 0.076655 | ||
| 12-1 Month Momentum % | -81.94 | ||
| 52-Week Range (€) | 0.0579 - 0.393 | ||
| Shares Outstanding (Mil) | 121.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kancera AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kancera AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kancera AB Frequently Asked Questions
What is Kancera AB(FRA:3EE0)'s stock price today?
The current price of FRA:3EE0 is €0.09. The 52 week high of FRA:3EE0 is €0.39 and 52 week low is €0.06.
When is next earnings date of Kancera AB(FRA:3EE0)?
The next earnings date of Kancera AB(FRA:3EE0) is 2025-02-21.
Does Kancera AB(FRA:3EE0) pay dividends? If so, how much?
Kancera AB(FRA:3EE0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers